Views & Analysis Weekly roundup: More questions for Novartis in Zolgensma sca... It’s been a tough month for Novartis, with the company facing a deepening scandal over data manipulation for its spinal muscular atrophy (SMA) gene therapy Zolgensma.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
